Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine

Clinical and Vaccine Immunology : CVI
Paul BalmerElizabeth Miller

Abstract

Recent changes to the childhood immunization schedule in the United Kingdom have resulted in the inclusion of the 7-valent pneumococcal conjugate vaccine. However, the seroprevalence of pneumococcal antibodies in the population was unknown. To address this, we measured pneumococcal, age-specific immunoglobulin G (IgG) concentrations specific for nine serotypes by an assay run on the Bioplex platform, using 2,664 serum samples collected in England from 2000 to 2004. The lowest concentrations of IgG specific to all serotypes and the proportions of serotype-specific IgG concentrations of >/=0.35 microg/ml were observed in children aged <1 year. From 1 year on, there was a general increase in antibody levels with increasing age, and they remained high in adults. Maternal antibody was detected in young children aged <36 days but waned rapidly. Comparison of the age-specific seroprevalence of serotype-specific IgG to the serotype-specific incidence of invasive pneumococcal disease demonstrated a general inverse relationship for all age groups except the elderly. These data provide a baseline for natural immunity to the pneumococcal serotypes analyzed prior to the introduction of pneumococcal conjugate vaccine in the United Kingdom.

References

Mar 1, 1978·The Journal of Infectious Diseases·J L DienstagR H Purcell
Aug 1, 1977·The Journal of Infectious Diseases·R GoldE C Gotschlich
Sep 24, 1988·BMJ : British Medical Journal·P Morgan-CapnerElizabeth Miller
Jul 1, 1969·American Journal of Diseases of Children·W C Cockburn
Feb 26, 1994·BMJ : British Medical Journal·Elizabeth MillerL Hindle
Sep 7, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S Romero-SteinerG M Carlone
Sep 24, 1999·The Pediatric Infectious Disease Journal·H ShinefieldJ Hansen
May 19, 2000·International Journal of Epidemiology·K OsborneElizabeth Miller
Jan 5, 2002·Scandinavian Journal of Infectious Diseases·B H NormarkG Källenius
Sep 30, 2003·Scandinavian Journal of Infectious Diseases·J HedlundGöran Kronvall
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanVaccine Trialists Group
Oct 30, 2003·The Cochrane Database of Systematic Reviews·K DearD Tatham
Mar 11, 2004·Clinical and Experimental Immunology·L BarilJ B McCormick
Feb 11, 2005·The Pediatric Infectious Disease Journal·Helena KäyhtyLennart Nilsson
Sep 27, 2005·Epidemiology and Infection·M HussainElizabeth Miller
Mar 29, 2006·The Pediatric Infectious Disease Journal·D GoldblattElizabeth Miller

Citations

May 17, 2013·Clinical and Vaccine Immunology : CVI·Xiaochun ZhangThomas M Daly
Feb 25, 2009·Clinical and Experimental Immunology·A MukherjeeS M Shalet
Nov 4, 2009·Clinical and Experimental Immunology·M BallowJ L Franco
Dec 29, 2009·The Journal of Infection·Caroline L TrotterElizabeth Miller
Dec 6, 2018·Frontiers in Immunology·Manish Sadarangani

Related Concepts

Prevnar
Antibodies, Bacterial
Antigens, Bacterial
Polyglobin
Pneumococcal Infections
Serotyping
Streptococcus pneumoniae
Seroprevalence
Age Distribution
Pneumovax

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.